Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
The PAS domains of AHR consist of two
2024-03-14

The PAS domains of AHR consist of two regions, PAS-A and PAS-B, which function as interfaces for dimerization with ARNT and for ligand binding, respectively [14]. Although both the bHLH and the PAS-A domains have been shown to be involved in dimerization with ARNT, a recent report suggests that only
-
br Adenosine receptors and innate immunity
2024-03-14

Adenosine receptors and innate immunity Monocytes and macrophages. All four adenosine receptor subtypes are expressed on monocytes and macrophages, and their levels and function undergo significant changes during the maturation of macrophages from monocytes. Indeed, quiescent monocytes are chara
-
angiotensin 2 receptor blocker The potential use of derivati
2024-03-14

The potential use of derivatives belonging to this series as therapeutic agents mostly depends on their pharmacokinetics and pharmacodynamics. The pharmacokinetic phase includes absorption, distribution, metabolism and excretion (ADME) of the studied compounds. Therefore, preliminary data for theore
-
Introduction Adenosine kinase ADK ATP adenosine phosphotrans
2024-03-14

Introduction Adenosine kinase (ADK; ATP: adenosine 5′-phosphotransferase, EC 2.7.1.20), is isolated from yeast cells by Kornberg for the first time in 1951 [1]. ADK belongs to the ribokinase protein family and is one of the most abundant nucleoside kinases in mammalian tissues [2,3]. As the first i
-
br Conclusion Biotransformation of trachyloban oic acid by S
2024-03-14

Conclusion Biotransformation of trachyloban-19-oic CP 31398 dihydrochloride mg by S. racemosum provided three products. Oxidation of compound 1 at C-17 (2–3), as well as rearrangement of 1 into a kaurane diterpene hydroxylated in C-16 and C-17 (4) were crucial for increasing AChE inhibitory activ
-
br Conclusion Our study of late life depression
2024-03-14

Conclusion Our study of late-life depression provides evidence of genotype-specific associations between depression and ACE methylation, as well as inverse correlations between ACE methylation and TCS PIM-1 1 secretion. These findings highlight the potential need to consider methylation levels i
-
As we previously observed in the NSFT Fukumoto et
2024-03-14

As we previously observed in the NSFT (Fukumoto et al., 2014), the effect of LY341495 in the FST was also inhibited by a 5-HT1A receptor antagonist, indicating the role of the 5-HT1A receptor in the actions of LY341495. Among the 5-HT1A receptors, which exist both presynaptically and postsynapticall
-
A role for YAP in mediating resistance to
2024-03-14

A role for YAP in mediating resistance to EGFR inhibition has also been described [28], [29]. In line with these evidences, we observed increased YAP activation in all the generated EGFR TKI–resistant cells, testified by decreased phosphorylation on the inhibitory serine 127, enhanced nuclear locali
-
br Materials and methods br
2024-03-14

Materials and methods Results Discussion The success of CAR-T cell therapy is based on two major facts: one is that cancer cells express tumor-associated antigens (TAAs) on their surface that can be detected by the human immune system; the other is that the CAR molecules target these TAAs o
-
br Acknowledgment br Introduction The yeast
2024-03-13

Acknowledgment Introduction The yeast Cdc48 ATPase and its metazoan ortholog p97 (or VCP) are critical components of many ubiquitin-dependent cellular pathways that require the segregation of individual proteins from binding partners or membranes (for review, see Buchberger, 2013, Meyer and We
-
SF1670 br Funding The present study was funded by
2024-03-13

Funding The present study was funded by The Scientific and Technological Research Council of Turkey (TUBITAK) within Research Program 1001, unique project number: 214S349. Introduction The apelin receptor, also called APJ or angiotensin receptor-like 1 was first cloned in 1993 due to its stro
-
The functions of HMGN protein are
2024-03-13

The functions of HMGN1 protein are modulated by various post-translational modifications, including phosphorylation , , , acetylation , and glycosylation . Phosphorylation in HMGN1 may influence its binding affinity to DNA or nucleosome-associated proteins and affect the sub-cellular localization an
-
Linagliptin is a recently approved dipeptidyl peptidase DPP
2024-03-13

Linagliptin is a recently approved dipeptidyl peptidase-4 (DPP-4) inhibitor and widely considered as first-line treatment for patients with type 2 diabetes. DPP-4 is responsible for the inactivation of incretin hormones, such as glucagon-like peptide 1 (GLP-1). GLP-1 is released by the intestine aft
-
In conclusion we identify in this report the molecular natur
2024-03-13

In conclusion, we identify in this report the molecular nature of the 12- and 15-lipoxygenases in M. mulatta and P. pygmaeus and also that the expression of the rhesus enzyme in lung epithelial cells is regulated by interleukin-4. The switch from a mainly 12-LO enzyme to a mainly 15-LO enzyme during
-
Although several ARIs have reached various phases of
2024-03-13

Although several ARIs have reached various phases of clinical experimentation however most of them have been withdrawn either due to an insufficient bioavailability, their poor efficacy or adverse side effects. Currently Epalrestat is in clinical use for the treatment of diabetic neuropathy. The sid
16931 records 204/1129 page Previous Next First page 上5页 201202203204205 下5页 Last page